Publications by authors named "Dirk Jaeger"

Claim this Profile
A
Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial.
Juanita Lopez, Thomas Powles, Fadi Braiteh, Lillian L Siu, Patricia LoRusso, Dirk Jaeger

Nat Med· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stratifying esophago-gastric cancer treatment using a patient-derived organoid-based threshold.
Tim Schmäche, Juliane Fohgrub, Anna Klimova, Karin Laaber, Stephan Drukewitz, Dirk Jaeger

Mol Cancer· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Ga-FAPI PET/CT on Staging and Oncologic Management in a Cohort of 226 Patients with Various Cancers.
Stefan A Koerber, Manuel Röhrich, Leon Walkenbach, Jakob Liermann, Peter L Choyke, Dirk Jaeger

J Nucl Med· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Role and Therapeutic Targeting of CCR5 in Breast Cancer.
Rasha Hamid, Mustafa Alaziz, Amanpreet S Mahal, Anthony W Ashton, Niels Halama, Dirk Jaeger

Cells· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcome and prognostic factors in patients undergoing salvage therapy for recurrent esophagogastric cancer after multimodal treatment.
Leonidas Apostolidis, Kristin Lang, Leila Sisic, Elena Busch, Aysel Ahadova, Dirk Jaeger

J Cancer Res Clin Oncol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab and maraviroc in refractory mismatch repair proficient/microsatellite-stable metastatic colorectal cancer - The PICCASSO phase I trial.
Georg Martin Haag, Christoph Springfeld, Barbara Grün, Leonidas Apostolidis, Stefanie Zschäbitz, Dirk Jaeger

Eur J Cancer· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
J
JunB is a key regulator of multiple myeloma bone marrow angiogenesis.
Fengjuan Fan, Stefano Malvestiti, Sonia Vallet, Judith Lind, Jose Manuel Garcia-Manteiga, Dirk Jaeger

Leukemia· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Publisher Correction: JunB is a key regulator of multiple myeloma bone marrow angiogenesis.
Fengjuan Fan, Stefano Malvestiti, Sonia Vallet, Judith Lind, Jose Manuel Garcia-Manteiga, Dirk Jaeger

Leukemia· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: First clinical experience.
Florian Eichhorn, Laura V Klotz, Mark Kriegsmann, Helge Bischoff, Marc A Schneider, Dirk Jaeger

Lung Cancer· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting the Risk of Metastases by PSMA-PET/CT-Evaluation of 335 Men with Treatment-Naïve Prostate Carcinoma.
Stefan A Koerber, Johannes Boesch, Clemens Kratochwil, Ingmar Schlampp, Jonas Ristau, Dirk Jaeger

Cancers (Basel)· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcome of PSMA-guided radiotherapy for patients with oligorecurrent prostate cancer.
Stefan A Koerber, Katharina Sprute, Clemens Kratochwil, Erik Winter, Matthias F Haefner, Dirk Jaeger

Eur J Nucl Med Mol Imaging· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer-related microangiopathic hemolytic anemia in patients with advanced gastric cancer: A retrospective single-center analysis.
Anne Katrin Berger, Michael Allgäuer, Leonidas Apostolidis, Anna Elisa Schulze-Schleithoff, Uta Merle, Dirk Jaeger

World J Gastrointest Oncol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Role of Ga-FAPI PET/CT for Patients with Malignancies of the Lower Gastrointestinal Tract: First Clinical Experience.
Stefan A Koerber, Fabian Staudinger, Clemens Kratochwil, Sebastian Adeberg, Matthias F Haefner, Dirk Jaeger

J Nucl Med· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recent Advances Targeting CCR5 for Cancer and Its Role in Immuno-Oncology.
Xuanmao Jiao, Omar Nawab, Tejal Patel, Andrew V Kossenkov, Niels Halama, Dirk Jaeger

Cancer Res· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COOLHAIR: a prospective randomized trial to investigate the efficacy and tolerability of scalp cooling in patients undergoing (neo)adjuvant chemotherapy for early breast cancer.
Katharina Smetanay, Philippe Junio, Manuel Feißt, Julia Seitz, Jessica Cecile Hassel, Dirk Jaeger

Breast Cancer Res Treat· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeted and immuno-biology driven treatment strategies for triple-negative breast cancer: current knowledge and future perspectives.
Carlo Fremd, Dirk Jaeger, Andreas Schneeweiss

Expert Rev Anticancer Ther· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomics and emerging biomarkers for immunotherapy of colorectal cancer.
Jakob Nikolas Kather, Niels Halama, Dirk Jaeger

Semin Cancer Biol· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer.
Yelena Y Janjigian, Johanna Bendell, Emiliano Calvo, Joseph W Kim, Paolo A Ascierto, Dirk Jaeger

J Clin Oncol· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-Throughput Screening of Combinatorial Immunotherapies with Patient-Specific Models of Metastatic Colorectal Cancer.
Jakob Nikolas Kather, Pornpimol Charoentong, Meggy Suarez-Carmona, Esther Herpel, Fee Klupp, Dirk Jaeger

Cancer Res· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors.
Mariano J Alvarez, Prem S Subramaniam, Laura H Tang, Adina Grunn, Mahalaxmi Aburi, Dirk Jaeger

Nat Genet· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeted BiTE Expression by an Oncolytic Vector Augments Therapeutic Efficacy Against Solid Tumors.
Tobias Speck, Johannes P W Heidbuechel, Rūta Veinalde, Dirk Jaeger, Christof von Kalle

Clin Cancer Res· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized controlled trial of S-1 maintenance therapy in metastatic esophagogastric cancer - the multinational MATEO study.
Georg-Martin Haag, Gertraud Stocker, Julia Quidde, Dirk Jaeger, Florian Lordick

BMC Cancer· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detailed resolution analysis reveals spatial T cell heterogeneity in the invasive margin of colorectal cancer liver metastases associated with improved survival.
Anna Berthel, Inka Zoernig, Nektarios A Valous, Christoph Kahlert, Fee Klupp, Dirk Jaeger

Oncoimmunology· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer.
Tomasz M Beer, Eugene D Kwon, Charles G Drake, Karim Fizazi, Christopher Logothetis, Dirk Jaeger

J Clin Oncol· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial.
Padmanee Sharma, Margaret K Callahan, Petri Bono, Joseph Kim, Pavlina Spiliopoulou, Dirk Jaeger

Lancet Oncol· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis